Stapled peptides designed from the Cullin3 protein bound to BTB domain targets with high affinity and improved stability, demonstrating potential for disrupting protein-protein interactions in the ubiquitin system.
~300-600 nM binding affinityThe stapled peptides bound their BTB domain targets with affinity comparable to the full-length Cullin3 protein, demonstrating that short, modified peptides can effectively mimic complex protein-protein interactions.
What the researchers found
Researchers designed stapled peptides based on the Cullin3 protein that successfully mimicked the protein-protein interaction between Cul3 and BTB domain-containing proteins. The stapled peptides adopted the correct helical structure (confirmed by CD and NMR), bound to BTB domains of KCTD11 (tetrameric) and KCTD5 (pentameric) with high affinity (~300-600 nM), and showed increased serum stability compared to unstapled peptides. The binding affinity was comparable to that of the full-length Cul3 protein with its natural BTB partners.
Why it matters
Stapled peptides are an emerging class of peptide therapeutics that can disrupt protein-protein interactions — targets traditionally considered 'undruggable' by small molecules. This study demonstrates that stapled peptides can effectively mimic a key protein interaction involved in the ubiquitin degradation system, which controls the breakdown of proteins involved in cancer and other diseases. The approach could lead to new drugs targeting the Cul3-BTB interface.
The numbers in context
Binding affinity ~300-600 nM · helix 2 residues 49-68 · hydrocarbon cross-linker stapling · increased serum stability · binds tetrameric KCTD11 and pentameric KCTD5
How the study worked
The study combined computational modeling with experimental techniques. Stapled peptides were designed from the Cul3 helix 2 region (residues 49-68) and stabilized with hydrocarbon cross-linkers. Their structure was characterized by circular dichroism (CD) and nuclear magnetic resonance (NMR) spectroscopy. Binding affinity to BTB domains was measured, and serum stability was assessed to evaluate their potential as therapeutic agents.
Who was studied
In vitro biochemical and biophysical study (no biological samples)
What this study cannot tell us
This is an in vitro study with no cellular or in vivo validation of the peptides' biological activity. While binding affinity was demonstrated, the ability of these stapled peptides to actually modulate Cul3-BTB-dependent processes in living cells was not tested. Cell permeability, a common challenge for stapled peptides, was not addressed.
How to read the evidence
This is an early-stage biochemical study demonstrating proof-of-concept for stapled peptide design targeting the Cul3-BTB interface. The structural and binding data are rigorous, but no biological or cellular validation has been performed.
When this study was published
Published in 2015, this study represents earlier work in the stapled peptide field. Since then, stapled peptide technology has advanced significantly, with several candidates entering clinical trials for cancer and other diseases.
The bigger picture
Stapled peptides represent one of the most promising frontiers in peptide therapeutics. Unlike regular peptides that are quickly degraded and can't penetrate cells easily, stapled peptides have improved stability and cell permeability. This study validates the approach for targeting protein-protein interactions in the ubiquitin-proteasome system — a pathway critical in cancer, neurodegeneration, and immune regulation — and expands the druggable target space for peptide-based therapies.
Questions still open
- Can these stapled peptides effectively penetrate cell membranes to disrupt Cul3-BTB interactions inside living cells?
- Could targeting the Cul3-BTB interface with stapled peptides selectively modulate specific protein degradation pathways in cancer?
- How do these stapled peptides compare to other approaches for disrupting protein-protein interactions, such as PROTACs?
Common questions
What are stapled peptides and why are they special?
Why is the Cullin3-BTB interaction important?
Read the original research
Cullin3-BTB interface: a novel target for stapled peptides.
PloS one, 10(4), e0121149
Citation
de Paola, Ivan; Pirone, Luciano; Palmieri, Maddalena; Balasco, Nicole; Esposito, Luciana; Russo, Luigi; Mazzà, Daniela; Di Marcotullio, Lucia; Di Gaetano, Sonia; Malgieri, Gaetano; Vitagliano, Luigi; Pedone, Emilia; Zaccaro, Laura. (2015). Cullin3-BTB interface: a novel target for stapled peptides.. PloS one, 10(4), e0121149. https://doi.org/10.1371/journal.pone.0121149